GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Earnings per Share (Diluted)

CytoSorbents (CytoSorbents) Earnings per Share (Diluted) : $-0.59 (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Earnings per Share (Diluted)?

CytoSorbents's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.59.

CytoSorbents's EPS (Basic) for the three months ended in Mar. 2024 was $-0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.59.

CytoSorbents's EPS without NRI for the three months ended in Mar. 2024 was $-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.58.

During the past 3 years, the average EPS without NRIGrowth Rate was -38.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -7.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.00% per year.

During the past 13 years, CytoSorbents's highest 3-Year average EPS without NRI Growth Rate was 47.80% per year. The lowest was -38.10% per year. And the median was 15.70% per year.


CytoSorbents Earnings per Share (Diluted) Historical Data

The historical data trend for CytoSorbents's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Earnings per Share (Diluted) Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -0.20 -0.57 -0.75 -0.64

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.14 -0.21 -0.12 -0.12

Competitive Comparison of CytoSorbents's Earnings per Share (Diluted)

For the Medical Devices subindustry, CytoSorbents's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's PE Ratio distribution charts can be found below:

* The bar in red indicates where CytoSorbents's PE Ratio falls into.



CytoSorbents Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

CytoSorbents's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-28.507-0)/44.656
=-0.64

CytoSorbents's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-6.358-0)/54.263
=-0.12

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


CytoSorbents  (NAS:CTSO) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CytoSorbents Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (CytoSorbents) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852